Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Ueno, Daiki ^a,b   Yao, Masahiro ^a,c   Tateishi, Ukihide ^a   Minamimoto, Ryogo ^a   Makiyama, Kazuhide ^a   Hayashi, Narihiko ^a   Sano, Futoshi ^a   Murakami, Takayuki ^a   Kishida, Takeshi ^d   Miura, Takeshi ^d   Kobayashi, Kazuki ^e   Noguchi, Sumio ^e   Ikeda, Ichiro ^e   Ohgo, Yoshiharu ^b   Inoue, Tomio ^a,c   Kubota, Yoshinobu ^a,d   Nakaigawa, Noboru ^a,d  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yokohama Sakae Kyosai Hospital   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLUORODEOXYGLUCOSE F 18; IOPAMIDOL; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLASSIFICATION; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84862231466     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-162     Document Type: Article

References (20)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell carcinoma in the United States. JAMA 1999, 281:1628-1631. 10.1001/jama.281.17.1628, 10235157.
2. Linehan WM, Walther MM, Alexander RB, Rosenberg SA. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. Semin Urol 1993, 11:41-43.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852. 10.1016/S0094-0143(03)00056-9, 14680319.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996, 335:865-875. 10.1056/NEJM199609193351207, 8778606.
5. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y. Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients. Eur Urol 2009, 57:317-326.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, . TARGET Study Group Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530, TARGET Study Group.
8. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, Sobrio F, Bouvard G, Agostini D. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003, 30:1236-1245. 10.1007/s00259-003-1211-4, 12845486.
9. Kang DE, White RL, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004, 171:1806-1809. 10.1097/01.ju.0000120241.50061.e4, 15076281.
10. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003, 21:3995-4000. 10.1200/JCO.2003.04.073, 14581422.
11. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009, 103:615-619. 10.1111/j.1464-410X.2008.08150.x, 19007371.
12. Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 2010, 10:667. 10.1186/1471-2407-10-667, 3016292, 21129184.
13. Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, Miura T, Makiyama K, Yao M, Kubota Y, Inoue T. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhnced CT. Clin Nucl Med 2010, 35(12):918-923. 10.1097/RLU.0b013e3181f9ddd9, 21206220.
14. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22(3):454-463.
15. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35(13):1773-1782. 10.1016/S0959-8049(99)00229-4, 10673991.
16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, . ARCC Global Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281. 10.1056/NEJMoa066838, 17538086, ARCC Global Trial.
17. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, . RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-456. Epub 2008 Jul 22, 10.1016/S0140-6736(08)61039-9, 18653228, RECORD-1 Study Group.
18. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011, 59(5):856-862. 10.1016/j.eururo.2011.01.038, 21306819.
19. Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010, 256(2):511-518. Epub 2010 Jun 15, 10.1148/radiol.10091362, 20551183.
20. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T. Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer. Clin Cancer Res 2011, 17:6021-6028. 10.1158/1078-0432.CCR-10-3309, 21742806.